Seattle Genetics is an attractive short term swing trade. The company currently has an approved product, ADCETRIS® (brentuximab vedotin), and focuses on antibody-drug conjugate technology. Click to read more about my technical analysis and ADC technology.
Arena Pharmaceuticals, is a company I see value in. The company’s leading pipeline is etrasimod, in which its worldwide Phase 3 trial for the treatment of moderately to severely active ulcerative colitis is currently in the planning process. Click the title of the post to read more.